The Chicago Entrepreneur

Biogen and Ionis Pharma shares slide as they end development of ALS treatment

The move comes after early-stage trial failed to result in a clear signal it slowed the disease process.

Previous post Cannabis stocks rise as U.S. moves to reclassify pot as less dangerous
Next post The NBA is picking its next TV partners — and a deal hinges on Warner Bros. Discovery’s next move